Contineum Therapeutics, Inc. Class A Common Stock (CTNM) - Total Liabilities
Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has total liabilities worth $10.38 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Contineum Therapeutics, Inc. Class A Com cash flow conversion to assess how effectively this company generates cash.
Contineum Therapeutics, Inc. Class A Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Contineum Therapeutics, Inc. Class A Com's assets to evaluate the company's liquid asset resilience ratio.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
China | CN¥211.52 Million |
|
Enviro Infra Engineers Ltd
NSE:EIEL
|
India | Rs4.36 Billion |
|
Melcor Developments Ltd.
TO:MRD
|
Canada | CA$813.47 Million |
|
Shenzhen Increase Technology Co Ltd Class A
SHE:300713
|
China | CN¥562.34 Million |
|
Zhejiang HISUN Biomaterials Co. Ltd. A
SHG:688203
|
China | CN¥542.63 Million |
|
Frp Holdings Ord
NASDAQ:FRPH
|
USA | $269.06 Million |
|
DI Dong Il Corp
KO:001530
|
Korea | ₩499.63 Billion |
|
HOMAG Group AG
F:HG1
|
Germany | €208.82 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Contineum Therapeutics, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CTNM market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 29.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Contineum Therapeutics, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Contineum Therapeutics, Inc. Class A Common Stock (2021–2024)
The table below shows the annual total liabilities of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.78 Million | -92.55% |
| 2023-12-31 | $198.32 Million | +1644.87% |
| 2022-12-31 | $11.37 Million | +27.28% |
| 2021-12-31 | $8.93 Million | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idio… Read more